Sanofi (NASDAQ:SNY) Reaches New 12-Month High – Time to Buy?

Sanofi (NASDAQ:SNY)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $60.12 and last traded at $59.35, with a volume of 3099845 shares trading hands. The stock had previously closed at $59.25.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on SNY shares. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Down 1.8 %

The stock’s 50-day moving average price is $53.27 and its two-hundred day moving average price is $52.81. The stock has a market capitalization of $146.41 billion, a P/E ratio of 23.17, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SNY. Abel Hall LLC boosted its holdings in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after purchasing an additional 194 shares during the period. Providence Capital Advisors LLC boosted its holdings in Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock valued at $2,653,000 after purchasing an additional 201 shares during the period. Angeles Investment Advisors LLC boosted its holdings in Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after purchasing an additional 210 shares during the period. Keudell Morrison Wealth Management raised its position in shares of Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after buying an additional 217 shares in the last quarter. Finally, Bailard Inc. raised its position in shares of Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after buying an additional 220 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.